CHMP recommend licence extension for ibrutinib (Imbruvica)

Ibrutinib is intended to be licensed as a single agent or in combination with rituximab or obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

European Medicines Agency